Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Igrelimogene Litadenorepvec,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : U.S. Department of Defense
Deal Size : $2.0 million
Deal Type : Funding
TILT Awarded $2 Million Grant from U.S. Department of Defense for Ovarian Cancer Research
Details : The funding aims to support the clinical development of TILT-123 (igrelimogene litadenorepvec) in combination with pembrolizumab for treating platinum-resistant/refractory ovarian cancer patients.
Product Name : TILT-123
Product Type : Microorganism
Upfront Cash : Undisclosed
February 14, 2024
Lead Product(s) : Igrelimogene Litadenorepvec,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : U.S. Department of Defense
Deal Size : $2.0 million
Deal Type : Funding
Details : The funding will be used to advance to Phase II the company’s combination trials of TILT-123 which use oncolytic immunotherapies synergistically with checkpoint inhibitors.
Product Name : TILT-123
Product Type : Microorganism
Upfront Cash : Undisclosed
July 02, 2023
Details : TILT-123 (igrelimogene litadenorepvec) is a 5/3 chimeric serotype adenovirus armed with two human cytokines, which is being evaluated in combination with avelumab for squamous cell carcinoma of head and neck, and melanoma.
Product Name : TILT-123
Product Type : Microorganism
Upfront Cash : Inapplicable
May 15, 2023
Details : TILT-123 is a human 5/3 chimeric adenovirus that has been engineered for targeting, safety and potency, is an oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), designed to stimulate T cells to better fight ...
Product Name : TILT-123
Product Type : Microorganism
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : Igrelimogene Litadenorepvec,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer
Details : The trial’s objective is to evaluate the safety and efficacy of TILT-123 in combination with pembrolizumab and is designed to also deliver insights about the mechanism of action of TILT-123 in humans.
Product Name : TILT-123
Product Type : Microorganism
Upfront Cash : Inapplicable
June 14, 2021
Lead Product(s) : Igrelimogene Litadenorepvec,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TILT Biotherapeutics has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus.
Product Name : TILT-123
Product Type : Microorganism
Upfront Cash : Inapplicable
May 05, 2021
TILT Biotherapeutics Secures Over EUR 6 million to Advance Cancer Immunotherapies Into Clinic
Details : Funds will be used to advance TILT's proprietary, best-in-class cytokine armed oncolytic adenovirus, TILT-123, into Phase 1 clinical trials in Europe and the United States, and to prepare for Phase 2 trials.
Product Name : TILT-123
Product Type : Microorganism
Upfront Cash : Undisclosed
June 16, 2020
Details : Under the agreement TILT has granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China.
Product Name : TILT-123
Product Type : Microorganism
Upfront Cash : Undisclosed
January 27, 2020
Reset All
